一种新的注射,RES-010,通过改变脂肪,有助于维持小鼠体重的下降,而tirzepatide则改善青少年的糖尿病和BMI。 A new injection, RES-010, helps maintain weight loss in mice by transforming fat, while tirzepatide improves diabetes and BMI in teens.

新的体重减重注射RES-010显示,通过重新规划身体处理脂肪和能量的方法,有望帮助保持长期体重减重。 A new weight loss injection, RES-010, shows promise in helping maintain long-term weight loss by reprogramming how the body processes fat and energy. 它的工作方式是堵塞一个叫做MIR-22的分子,刺激mitochondria活性,以及将能量储存的白脂肪转化为热量燃烧的棕色脂肪。 It works by blocking a molecule called miR-22, boosting mitochondria activity, and converting energy-storing white fat into calorie-burning brown fat. 小鼠早期研究显示,在治疗停止后,体重持续下降,但没有恢复体重。 Early studies in mice showed sustained weight loss without regaining weight after treatment stopped. 同时,tirzepatide(Mounjaro)展示了对10至17岁患有2型糖尿病的儿童的重大好处,改善了血糖,并减少了血糖指数。 Meanwhile, tirzepatide (Mounjaro) demonstrated significant benefits in children aged 10 to 17 with type 2 diabetes, improving blood sugar and reducing BMI. 这两种治疗都有可能持久地改善新陈代谢,但还需要开展更多的研究,以确认人类的长期安全和有效性。 Both treatments offer potential for lasting metabolic improvements, though more research is needed to confirm long-term safety and effectiveness in humans.